The tightening of advertising restrictions on regenerative treatments such as PRP, PRF, stem cell therapies, and other plasma-related procedures is now a problem. It is creating a major headache for aesthetic clinic owners in both sides of the Atlantic. These treatments have become to define the future of non-surgical aesthetic medicine. Particularly in areas like hair restoration and skin rejuvenation.
For the purpose of this article we will not focus on plentiful uses of regenerative medicine in strictly medical settings. There are many. We will focus on beauty instead. Thanks to increasingly strict advertising regulations, aesthetic clinics now find themselves in a frustrating limbo. They are left unable to promote these highly sought-after treatments through normal marketing channels or calling them by their name.
The crackdown doesn’t stop there. Any treatment that falls under the umbrella of prescription-only medicines (aka POMs) is banned from advertising. Botox, fat loss injections, ketamine infusions and biohacking therapies are also being heavily policed and restricted. While the stated intent behind these regulations is to protect consumers from misleading claims or unregulated practitioners, the reality is very different. Legitimate and highly qualified clinics are being silenced alongside the bad actors. The question is, how are clinics supposed to attract patients when they can’t even name the treatments they provide?
For regenerative treatments in particular, the problem is even more severe. There are only so many ways you can describe PRP for hair loss or PRF for skin rejuvenation without outright saying what it is. Botox has generic alternatives like “anti-wrinkle injections” which are now also under threat, with authorities preferring even more generic terms such as “anti-wrinkle treatment“. This however does not describe Botox adequately. PRP is even in a worse state. It doesn’t have an easy substitute. It is what it is. Literally.
What this means is that clinics are now expected to talk around the treatment in a vague, often unhelpful way. Ironically competitors (such as skin care companies) offering less effective, over-the-counter solutions face no such restrictions. Quite the opposite. They enjoy more prominence as they dominate generic terms in search results.
This is where the industry faces a major paradox. On one hand, regenerative medicine is the future of aesthetics, promising long-term results and natural rejuvenation without synthetic substances. On the other, clinic owners are being backed into a corner, unable to market these cutting-edge treatments effectively. The impact of these restrictions is clear: they stifle innovation, limit consumer awareness, and create an unfair advantage for big-name, non-medical beauty brands that don’t have to navigate the same regulatory minefield.
The reality is, patients still want these treatments. Hair loss sufferers aren’t going to stop searching for PRP just because clinics can’t advertise it. But without clear, accessible marketing, patients may struggle to find regulated, reputable practitioners. That helps pushing them toward the black market or overseas clinics with questionable standards. This is exactly the opposite of what regulators claim to be aiming for.
So where does this leave UK clinics? Many are turning to SEO-driven content marketing, private networks, and word-of-mouth referrals to fill the gap. But that might not be enough. Some are experimenting with indirect marketing tactics, using education-based approaches like blogs and patient testimonials to hint at their offerings without explicitly naming them.
Typical Advertising Restrictions for Aesthetic Clinics
| Restriction Category | Specific Examples | Rationale |
| Prescription-Only Medicines (POMs) | Botox (botulinum toxin) and other brand names. Any other prescription medications used in treatments. Directly promoting or naming POMs in ads. | Ensures that these medications are administered only under proper medical supervision. Prevents inappropriate use from consumer demand driven by advertising. |
| Misleading Claims | Guaranteed results. Exaggerated before-and-after photos. Unsubstantiated claims about treatment efficacy. | Protects consumers from false expectations and potential harm. Maintains trust in the medical profession. |
| Targeting Under-18s | Advertising cosmetic interventions directly to minors. Ads appearing on platforms primarily used by minors. | Protects vulnerable young people from pressure to undergo cosmetic procedures. Addresses concerns about body image and self-esteem. |
| Trivializing Procedures | Downplaying the seriousness of cosmetic procedures, suggesting they are casual or inconsequential. Time limited discount offers to push patients into decisions. | Reinforces that these are medical procedures with potential risks. Upholds responsible advertising. |
| Speculative or Experimental Treatments | Stem cell therapies with unclear scientific consensus. Unproven gene therapies. | Protects consumers from potentially harmful or ineffective treatments. Maintains scientific integrity. |
| Medical Devices regulations. | Using medical device brand names, and unproven results involving their usage. | Ensures patient safety, and promotes the ethical usage of medical devices. |
| Body Image exploitation | Ads that portray an unhealthy body image as aspirational, or exploits people insecurities. | Protects the public from harmful advertising. |
However, these are workarounds. Not real-life solutions. Digital advertising, social media, and traditional marketing remain the most powerful tools for growing an aesthetic practice. And like with most other sectors, without access to them, many clinics are losing business and struggling to compete.
The industry is at a crossroads. If regenerative medicine is truly the future, regulators need to rethink their approach. There’s a difference between banning unethical claims and preventing legitimate clinics from speaking plainly about their services. Until that distinction is clearly established, aesthetic clinics will continue to operate under a cloud of uncertainty. And the patients? Ironically, they become less protected, not more.
